Zurich Cantonal Bank’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.41M Buy
13,412
+3,339
+33% +$296K ﹤0.01% 1229
2025
Q4
$880K Hold
10,073
﹤0.01% 1420
2025
Q3
$669K Hold
10,073
﹤0.01% 1555
2025
Q2
$557K Buy
10,073
+981
+11% +$47.1K ﹤0.01% 1588
2025
Q1
$440K Sell
9,092
-610
-6% -$25.6K ﹤0.01% 1676
2024
Q4
$374K Sell
9,702
-126
-1% -$5.49K ﹤0.01% 1802
2024
Q3
$442K Sell
9,828
-16
-0.2% -$646 ﹤0.01% 1634
2024
Q2
$341K Sell
9,844
-19
-0.2% -$556 ﹤0.01% 1757
2024
Q1
$285K Sell
9,863
-475
-5% -$12.9K ﹤0.01% 1842
2023
Q4
$237K Buy
10,338
+1,093
+12% +$19.1K ﹤0.01% 1987
2023
Q3
$154K Sell
9,245
-465
-5% -$9.02K ﹤0.01% 2129
2023
Q2
$268K Sell
9,710
-450
-4% -$11.3K ﹤0.01% 1725
2023
Q1
$234K Buy
10,160
+1,624
+19% +$27.3K ﹤0.01% 1774
2022
Q4
$93.1K Buy
8,536
+1,337
+19% +$11.3K ﹤0.01% 2317
2022
Q3
$61K Hold
7,199
﹤0.01% 2521
2022
Q2
$57K Hold
7,199
﹤0.01% 2537
2022
Q1
$170K Buy
7,199
+906
+14% +$25.5K ﹤0.01% 1992
2021
Q4
$215K Buy
6,293
+3,864
+159% +$122K ﹤0.01% 2020
2021
Q3
$43K Buy
+2,429
New +$104K ﹤0.01% 2656

Other funds holding PTGX

Zurich Cantonal Bank's PTGX Position: Q1 2026 in Review

Zurich Cantonal Bank increased its Protagonist Therapeutics (PTGX) stake by 33% in Q1 2026, buying an estimated $296K and bringing the position to 13,412 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Zurich Cantonal Bank first reported a position in PTGX in Q3 2021 and has held it in 19 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Zurich Cantonal Bank held 13,412 shares of Protagonist Therapeutics worth $1.41M as of Q1 2026.
  • Zurich Cantonal Bank bought 3,339 Protagonist Therapeutics shares in Q1 2026, an estimated $296K.
  • Protagonist Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1229 holding.
  • Zurich Cantonal Bank first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.